329 The Investigational Drug MLN0264 First-in-human, First in Class ADC Targeting GCC: Phase I Dose-escalation Study and Supportive Scientific Rationale
| Autor: | Veiby, P., Zhang, J., Yang, J., McDonald, A., Fasanmade, A., Wyant, T., Almhanna, K., Kalebic, T. |
|---|---|
| Zdroj: | In European Journal of Cancer November 2012 48 Supplement 6:101-101 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect